Tag: Methylxanthine PDE inhibitor / hemorheologic agent

  • Pentoxifylline

    Methylxanthine PDE inhibitor / hemorheologic agent

    A methylxanthine non-selective phosphodiesterase inhibitor that improves erythrocyte deformability and microcirculation; used for intermittent claudication.

    Abstract

    Pentoxifylline (1-(5-oxohexyl)-3,7-dimethylxanthine; CAS 6493-05-6; molecular formula C13H18N4O3; molecular weight 278.31) is a methylxanthine non-selective phosphodiesterase inhibitor developed at Hoechst (now Sanofi) and approved by the FDA in 1984 under the trade name Trental. Mechanism: weak non-selective PDE inhibition (PDE3, PDE4, PDE5) increases intracellular cAMP and cGMP. The principal clinically meaningful effect is improvement in erythrocyte deformability and reduced platelet aggregation, producing improved microcirculatory blood flow. Approved for intermittent claudication. Off-label use in chronic cognitive impairment from small-vessel cerebrovascular disease, peripheral neuropathy, and tinnitus. Plasma half-life is approximately 0.4 to 0.8 hours; metabolism is hepatic. Used as a reference hemorheologic agent and weak non-selective PDE inhibitor.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.